Akynzeo for nausea in endometrial cancer chemo
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if Akynzeo (a nausea medicine) helps prevent vomiting during chemotherapy for endometrial cancer. It is for people starting chemo for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have endometrial cancer diagnosed by a biopsy
- You have not had chemotherapy before
- You are able to be active at least up to light housework or office work
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You are not taking long-term steroid medication or have brain metastases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called IV NEPA (fosnetupitant/palonosetron) to prevent nausea and vomiting in children who are receiving strong chemotherapy. Patients will receive at least one cycle of chemotherapy that is highly likely to cause these side effects.
This trial tests a medication called LY3537021 to see if it can prevent nausea and vomiting caused by certain types of chemotherapy (AC or cisplatin) in people who have not had chemo before. It focuses on patients who are otherwise in fairly good health.
This trial tests a new form of megestrol acetate to prevent nausea and vomiting caused by chemotherapy in people with advanced stomach cancer who haven't had chemo before. It's for those starting a specific chemo combo that includes a PD-1 inhibitor and CAPOX.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
This Phase 4 study tests whether taking anti-nausea medicines through a vein (IV) or by mouth (oral) works better when combined to prevent nausea from breast cancer chemotherapy. It also checks safety, meaning side effects and how well people tolerate the medicines.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.